CN104519882A - 治疗赛多孢子菌属感染的方法 - Google Patents

治疗赛多孢子菌属感染的方法 Download PDF

Info

Publication number
CN104519882A
CN104519882A CN201380029050.6A CN201380029050A CN104519882A CN 104519882 A CN104519882 A CN 104519882A CN 201380029050 A CN201380029050 A CN 201380029050A CN 104519882 A CN104519882 A CN 104519882A
Authority
CN
China
Prior art keywords
acyl
compound
alkyl
hydrogen
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380029050.6A
Other languages
English (en)
Chinese (zh)
Inventor
朱莉·菲利普斯
塔尼亚·索雷尔
莎伦·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biodiem Ltd
Original Assignee
Biodiem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902243A external-priority patent/AU2012902243A0/en
Application filed by Biodiem Ltd filed Critical Biodiem Ltd
Publication of CN104519882A publication Critical patent/CN104519882A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380029050.6A 2012-05-30 2013-05-13 治疗赛多孢子菌属感染的方法 Pending CN104519882A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012902243 2012-05-30
AU2012902243A AU2012902243A0 (en) 2012-05-30 Method of treating Seedosporium spp. infection
PCT/AU2013/000487 WO2013177608A1 (en) 2012-05-30 2013-05-13 Method of treating scedosporium spp. infection

Publications (1)

Publication Number Publication Date
CN104519882A true CN104519882A (zh) 2015-04-15

Family

ID=49672167

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380029050.6A Pending CN104519882A (zh) 2012-05-30 2013-05-13 治疗赛多孢子菌属感染的方法

Country Status (9)

Country Link
US (1) US9867802B2 (https=)
EP (1) EP2854799B1 (https=)
JP (1) JP2015518007A (https=)
CN (1) CN104519882A (https=)
AU (2) AU2013204604B2 (https=)
CA (1) CA2874881A1 (https=)
SG (1) SG11201407924RA (https=)
WO (1) WO2013177608A1 (https=)
ZA (1) ZA201408975B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018310749A1 (en) * 2017-08-01 2020-02-20 Opal Biosciences Limited Treatment of Staphylococcal and Enterococcal infections using substituted nitrostyrene compounds
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
EP3877371A4 (en) 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
WO2020097398A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
CA3181537A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202325289A (zh) 2021-11-09 2023-07-01 美商雅捷可斯治療公司 Ｊａｋ２抑制劑之形式及組合物
JP7782035B2 (ja) 2021-11-09 2025-12-08 エイジャックス セラピューティクス， インコーポレイテッド Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863788A (zh) * 2001-06-18 2006-11-15 拜欧戴姆有限公司 抗菌和防辐射化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985761A (en) * 1974-10-24 1976-10-12 Sarabhai Research Centre Nitrothiazolyl derivatives of nitrostyrene
JPS585902B2 (ja) * 1978-09-01 1983-02-02 株式会社大塚製薬工場 β↓−ニトロスチレン誘導体
US20080220103A1 (en) * 2005-10-24 2008-09-11 Jay Birnbaum Method for treating/controlling/killing fungi and bacteria on living animals
WO2007050242A1 (en) * 2005-10-24 2007-05-03 Staval Pharma, Ltd. Method for treating/controlling/killing fungi and bacteria
WO2008061308A1 (en) * 2006-11-22 2008-05-29 Biodiem Ltd Protein tyrosine phosphatase modulators
JP2011518844A (ja) * 2008-04-25 2011-06-30 ナノバイオ コーポレーション 真菌、酵母および糸状菌感染症を治療するためのナノエマルション
UA107963C2 (xx) * 2010-06-07 2015-03-10 Janssen Pharmaceutica Nv ПРОТИГРИБКОВІ ПОХІДНІ 5,6-ДИГІДРО-4-$(ДИФТОРЕТИЛ)ФЕНІЛ]-4H-ПІРОЛО$1,2-a]$1,4]БЕНЗОДІАЗЕПІНУ І 4-(ДИФТОРЕТИЛ)ФЕНІЛ-6H-ПІРОЛО$1,2-a]$1,4]БЕНЗОДІАЗЕПІНУ

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863788A (zh) * 2001-06-18 2006-11-15 拜欧戴姆有限公司 抗菌和防辐射化合物
CN101804047A (zh) * 2001-06-18 2010-08-18 拜欧戴姆有限公司 抗菌和防辐射化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
万喆等: "卡泊芬净联合伏立康唑、伊曲康唑或两性霉素Ｂ对尖端赛多孢子菌体外抑菌活性", 《中国临床药理学杂志》, vol. 26, no. 7, 31 July 2010 (2010-07-31), pages 499 - 501 *
吕雪莲等: "赛多孢子菌病", 《中华皮肤科杂志》, vol. 42, no. 3, 31 March 2009 (2009-03-31), pages 218 - 222 *

Also Published As

Publication number Publication date
JP2015518007A (ja) 2015-06-25
EP2854799B1 (en) 2018-04-25
AU2013270430A1 (en) 2014-12-18
ZA201408975B (en) 2016-10-26
AU2013204604B2 (en) 2016-05-19
WO2013177608A1 (en) 2013-12-05
EP2854799A1 (en) 2015-04-08
HK1209052A1 (en) 2016-03-24
SG11201407924RA (en) 2014-12-30
AU2013204604A1 (en) 2013-12-19
US9867802B2 (en) 2018-01-16
EP2854799A4 (en) 2015-10-21
US20150126436A1 (en) 2015-05-07
CA2874881A1 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
CN104519882A (zh) 治疗赛多孢子菌属感染的方法
AU2014323822B2 (en) Immune adjustment compound, use thereof and pharmaceutical composition comprising same
ES2437346T3 (es) Procedimiento para la producción de derivado de diamina
JP2009263372A (ja) 抗微生物及び放射線防御化合物
JP2009263372A6 (ja) 抗微生物及び放射線防御化合物
JP2004501901A (ja) イミノピリミジン系ｎｍｄａｎｒ２ｂ受容体拮抗薬
US20240374573A1 (en) Imidazole containing compounds, derivatives therefore, and uses thereof
US20230029009A1 (en) Chemical compounds
BRPI0810192B1 (pt) aspartato do ácido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diaza-espiro [3,4] oct-6-il)-4-oxo-1,4-diidro- [1,8] naftiridina-3-carboxílico, método para preparação do mesmo e composição farmacêutica antimicrobiana compreendendo o mesmo.
US10570144B2 (en) Substituted ureas as prostaglandin EP4 receptor antagonists
RU2434867C2 (ru) Производные бензохинолизин-2-карбоновой кислоты
US20260069585A1 (en) ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
WO2019042443A1 (zh) 一类具有降解酪氨酸蛋白激酶jak3活性的化合物
US20070004777A1 (en) Methods for treating or preventing acute myelogenous leukemia
CN111499623B (zh) 一类非核苷抗肿瘤药物的噻唑酮脲衍生物及其药物用途
HK1209052B (en) 3,4-methylenedioxy-beta-methyl-beta-nitrostyrene for use in the treatment of scedosporium spp. infection
US20260069553A1 (en) TAPINAROF AND ANALOGS THEREOF FOR USE IN TREATING AhR MEDIATED DISEASES
JP5714602B2 (ja) 新規な２−アルキニル−ｎ９−プロパギルアデニンおよびその医薬用途
JP2017105714A (ja) 多剤排出ポンプ阻害剤
TW202408517A (zh) Rlip76抑制劑
WO2022128746A1 (en) Quinoline derivatives as endoparasiticides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150415

WD01 Invention patent application deemed withdrawn after publication